Skip to content
ppharmaranks
Menu

Best Microtubule Inhibitor for breast neoplasms

Top-rated pick: Taxotere — pharmaranks score 70/100, the highest of the 4 Microtubule Inhibitor drugs used for breast neoplasms, ranked by our independent FDA recall-safety score. Compare them with all treatments for breast neoplasms or the full Microtubule Inhibitor class. Not medical advice — always consult a professional.

Quick answer: Of the 4 microtubule inhibitor drugs we rate for breast neoplasms, none are yet flagged as generics in our price data, and most are injectable. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for breast neoplasms; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 17, 2026·How we rate

Top microtubule inhibitor for breast neoplasms: 1. Taxotere · 2. Docivyx · 3. Eribulin Mesylate

Best-rated Microtubule Inhibitor for breast neoplasms, ranked by pharmaranks score
#DrugRatingPharmacy pays
170/100View →
2Not yet ratedView →
3Not yet ratedView →
4Not yet ratedView →

Full ranking · 4 drugs

Frequently asked

What is the best microtubule inhibitor for breast neoplasms?
By our independent recall-safety rating — not an efficacy measure — taxotere ranks highest among Microtubule Inhibitor drugs used for breast neoplasms. Always consult a professional.
Which microtubule inhibitor drugs treat breast neoplasms?
pharmaranks lists 4 Microtubule Inhibitor products used for breast neoplasms, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.